|
The 5 Ways Flexcin™ Promotes Healthy
Joints!...
|
|
|
|
A Recent Clinical Study...
|
| |
|
(The following is a summary of one recent
clinical study. Many other studies have been conducted into
the efficacy of the ingredients contained in Flexcin's™
proprietary R3TS™ formula. For a complete listing of
references, see footnotes below.)
A multi-center, clinical research study was recently conducted
by Dr. H. Siemandi, M.D., Ph.D. in California, involving 382
patients who had been diagnosed with degenerative joint disease,
rheumatoid arthritis, and psoriatic arthritis. Each patient
was evaluated on their function/mobility according to the
following established measurement criteria:
|
| |
| - Joint Swelling |
- Urinalysis |
| - Joint Pain |
- Radiographic Assessment |
| - Chest Expansion |
- Patient Assessment |
| - Blood Analysis |
- Physician Assessment |
|
| |
|
The objective of this study was to compare the efficacy and
safety of treatment with an oral, Cetyl Myristoleate-based
Complex versus a placebo in subjects clinically diagnosed
with unhealthy joints.
The study was performed as a randomized, double-blind, placebo-controlled
parallel trial. The patients were divided into three groups
and tested for a period of one month.
The first group (A) received a complex of fatty acids containing
CM8™ (Cetyl Myristoleate) (similar to the bio-enriched
form found in Flexcin™).
|
|
The second group (B) received the same complex plus Glucosamine
hydrochloride, sea cucumber, and hydrolyzed cartilage (similar,
but less-effective derivatives of the proprietary ingredients
present in Flexcin™).
|
|
The third group (C) received a placebo. At the conclusion
of the study, the outcome measures included patient-reported
, clinical, laboratory, and radiograph assessments.
|
|
The astounding results were recorded in the Townsend Letter
for Doctors and Patients (reported in percentage of improvement):
|
| |
| |
Group A
|
Group B
|
Group C
|
| Treatment Response |
63.30%
|
87.30%
|
14.50%
|
| MD Overall Assessment |
58.10%
|
84.20%
|
13.90%
|
| Patient Overall Assessment |
59.20%
|
88.20%
|
16.10%
|
| Joint Swelling Score |
47.50%
|
77.20%
|
21.10%
|
|
| |
|
The remarkable results showed a significant improvement of
63.3% in Group A, which received CM8™ (Cetyl Myristoleate)
alone.
|
|
|
|
In Group B, the addition of complimentary elements, (creating
an enhanced Cetyl Myristoleate-based "complex")
resulted in an even more astounding improvement averaging
over 87%!
|
|
|
|
By contrast, Group C (the group which receive the placebo)
only reported a 14.5% improvement.
|
|
|
|
To fully appreciate the absolutely ASTOUNDING results of
this study, let's put it in proper perspective by comparing
it to test results from two common "prescription drugs."
|
|
|
|
As discussed in Arthritis in the Johns Hopkins White
Papers (Simeon, Margolis, MD, Ph.D., and John A. Flynn, MD),
two drugs commonly used to treat rheumatoid arthritis in those
who do not respond to non-steroidal anti-inflammatory drugs
(NSAIDS) are methotrexate and cyclosporin.
|
|
|
|
One study showed that when taken together, these two powerful
drugs proved to be ONLY 20% effective in relieving
the symptoms of rheumatoid arthritis. Those taking methotrexate
alone saw a 16% improvement. Methotrexate has been shown to
harm the liver, and biopsies (the actual practice of REMOVING
a piece of the liver) are routinely recommended for patients
taking this medication to monitor liver damage.
|
|
|
|
In addition, when taking these "drugs," blood tests
are also performed every 4 to 8 weeks to assess any possible
damage.
|
|
|
|
CONCLUSION:
|
|
As you can see from this comparison alone, the results achieved
in the CM8™ (Cetyl Myristoleate) Complex Group reported
an improvement of more than 400% over similar
patients treated with more "traditional drugs."
|
|
|
|
The significant results of this clinically-validated study
attest to the high-efficacy of Flexcin™ (whose proprietary
R3TS™ Complex actually contains a similar, but highly-advanced,
much more potent formulation than the CM8™ (Cetyl-Myristoleate)
based group received).
|
|
|
|
Exploratory analysis show encouraging results and indicate
that Flexcin™ health-modifying properties in relation
to joint discomfort.
|
|
|
|
REFERENCES: 1) "Effects
of Modulation of Inflammatory and Immune Parameters in Patients
with Rheumatic and Inflammatory Disease Receive Dietary Supplementation
of N-3 and N-6 Fatty Acids." Kremer, Jl, MD, Lipids -
2) "Botanical Lipids: Effects in Inflammation, Immune
Response, and Rheumatoid Arthritis." Rothman. D., et
al. Seminars in Arthritis and Rheumatism - 3) "Anti-Inflammatory
Diet in Rheumatic Disease," Adam, O. European Journal
of Clinical Nutrition - 4) "Glycosaminoglycan Supplements
as Therapeutic Agents." Bucci, L., Ph.D.., Nutritional
Report - 5) "The Biological Activity of Bovine Cartilage
Preparations." Prudden, J. MD, Balassa, L., Seminars
in Arthritis and Rheumatism.
|
